Blood Cancer New Drug Hopefuls Sell Off Shares Worth Billions Amid Stock Surge

Joseph P. Rischatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (Nasdaq: ELVN), a developer of targeted therapies for hematologic malignancies, sold approximately 130,000 shares on the Nasdaq on January 8–9 through his personal trust under a pre-established Rule 10b5-1 trading plan, realizing about $3.25 million (roughly KRW 4 billion). He still indirectly holds several hundred thousand shares.

Chief Operating Officer Anishi Patel also liquidated around 48,000 shares on the same day via a family trust under a Rule 10b5-1 plan, converting approximately $1.35 million (mid-KRW 1 billion range) into cash, and remains reported to hold over 200,000 shares through that trust.

Following the release of initial Phase 1b data for its chronic myeloid leukemia (CML) targeted therapy ELVN-001, Enliven’s stock surged nearly 50% in a short span and briefly hit a 52-week high of $25.64 on January 9. Technical indicators also reflected heightened market interest, with the Relative Strength Index (RSI) climbing into the 80s.

Building on anticipated positive clinical results in 2025, the company is preparing to initiate Phase 3 of ELVN-001 in 2026. In January, it restructured its board for the commercialization phase by appointing Scott Garland as a new director.

Headquartered in Boulder, Colorado, Enliven Therapeutics is a clinical-stage biotech focused on developing small-molecule precision oncology therapies aimed at extending survival and improving quality of life for patients with hematologic cancers, including CML.

With its lead BCR-ABL1–targeted candidate ELVN-001 listed on Nasdaq, the company’s entry into Phase 3 and readiness for commercialization are expected to drive its enterprise value and shape market perceptions of insider stock transactions.